Lava -Model 1207 -Pipeline
LAVA-1207, a gamma-delta bsTCE targeting the prostate specific membrane antigen (PSMA), has also demonstrated preclinical proof-of-concept. We expect to initiate a Phase I/IIa trial in metastatic castration-resistant prostate cancer in the second half of 2021.
Most popular related searches
Early-Stage Pipeline
In addition to our two named lead programs, we are advancing a portfolio of early-stage programs.
